Adverse effects related to intravenous infusion of cyclophosphamide in patients in a referral hospital

Lugo, María Elvira Miskinich; Duré, César Damián Riveros; Rotela, Auda Alice Quintana; Franco, Elvis Javier Ibáñez; Cristaldo, José David Cabañas; Díaz, Mónica Martínez Ruiz; Britez, Delcy Verónica; Méreles, Kathia Gisselle Medina; Montiel, Dora

doi:10.18004/rpr/2022.08.01.11

Cited by 1 publication

(1 citation statement)

References 9 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tools allowed for the determination of primary measurements, such as tail length (TL) and the tail DNA percentage (Tail DNA %) which were used to calculate the Tail Moment TM % Tail Length Tail DNA 100 = # ^h , as proposed by Tice et al [39]. In particular, the (Tail DNA %) measure is recommended in the scientific literature, as it helps reduce variability in the results, as indicated by Kumaravel et al [40].…”

Section: Statistical Analysesmentioning

confidence: 99%

Assessment of metronomic chemotherapy–induced DNA damage in peripheral blood leukocytes from canine mammary cancer patients using the alkaline comet assay

Chalco–Torres,

Aranguren–Méndez,

Guerrero–López

et al. 2024

RC FCV-LUZ

View full text Add to dashboard Cite

Mammary cancer is a disease that requires effective treatments. Conventional chemotherapy, while effective, often causes harmful side effects. In contrast, metronomic chemotherapy (mCHT), which involves the continuous administration of low doses of anticancer drugs, is presented as a less aggressive alternative. In this study, the genotoxic impact of treatment with Cyclophosphamide and Meloxicam under the mCHT approach was evaluated in ten canine (Canis lupus familiaris) patients with mammary carcinoma after undergoing mastectomy. The patients underwent monthly evaluations, including chest X–rays, blood tests, and the alkaline comet assay to measure genotoxic effects of the antineoplastic drugs. These results were compared with those of a group that received conventional chemotherapy. The results revealed that patients treated with mCHT experienced significantly lower levels of DNA damage compared to those who received conventional chemotherapy. Furthermore, DNA damage decreased over time during mCHT, suggesting that dogs may have developed tolerance to the treatment. Blood parameters remained stable in the mCHT–treated group, and X–rays showed no signs of recurrence or metastasis. All dogs survived during the one–year follow–up without mammary cancer recurrence. It is concluded that mCHT with Cyclophosphamide appears to be a less aggressive therapeutic option with a more favorable genotoxic profile in the treatment of mammary cancer in dogs.

show abstract

Section: Statistical Analysesmentioning

confidence: 99%